污水處理設備 污泥處理設備 水處理過濾器 軟化水設備/除鹽設備 純凈水設備 消毒設備|加藥設備 供水/儲水/集水/排水/輔助 水處理膜 過濾器濾芯 水處理濾料 水處理劑 水處理填料 其它水處理設備
上海研盟生物科技有限公司
“Anti-FABP3抗體,脂肪酸結合蛋白3抗體“抗體規格0.1ml、0.2ml、1ml,抗體產品有效期一年,質保三個月,質保期內出現任何質量問題或是出不了實驗結果均可免費退換:
上海研盟生物科技有限公司Anti-FABP3抗體,脂肪酸結合蛋白3抗體*,主要應用于WB、IHC、IF、ELISA、流式細胞術等實驗中。說明書隨貨發送,您也可以直接我司在線客服索取。客服
簡單介紹:
中文名稱:脂肪酸結合蛋白3抗體
英文名稱:Anti-FABP3
產品編號:byk-11283R
產品別名:Muscle fatty acid binding protein; 422 protein; Cardiac Fatty Acid Binding Protein; FABP 11; FABP 3; FABP11; FABP3; FABPH_HUMAN; Fatty acid binding protein 11; Fatty acid binding protein 3; Fatty acid binding protein 3 muscle and heart; Fatty acid binding protein 3 muscle and heart mammary derived growth inhibitor; Fatty acid binding protein 3 muscle; Fatty acid binding protein 3, muscle and heart (mammary derived growth inhibitor); Fatty acid binding protein 3, muscle; Fatty acid binding protein heart; Fatty acid binding protein, heart; Fatty acid-binding protein 3; Fatty acid-binding protein; H FABP; H-FABP; Heart type fatty acid binding protein; Heart-type fatty acid-binding protein; M FABP; M-FABP; Mammary derived growth inhibitor; Mammary-derived growth inhibitor; MDGI; Muscle fatty acid-binding protein; Mylein protein P2 homolog; O FABP; P2 adopocyte protein.
產品用途:科研實驗
產品價格:請報價
說明書:請添加客服直接索取
抗體來源:該指標有兩種產品,一種是兔來源抗體,一種是鼠來源抗體
克隆類型:兔來源為多克隆抗體,鼠來源單克隆抗體
交叉反應:請索取說明書查看
性 狀:Lyophilized or Liquid
濃 度:1mg/1ml
亞 型:IgG
純化方法: affinity purified by Protein A
儲 存 液: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol
保存條件: Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Anti-FABP3抗體,脂肪酸結合蛋白3抗體產品介紹:Fatty acid-binding proteins, designated FABPs, are a family of homologous cytoplasmic proteins that are expressed in a highly tissue-specific manner and play an integral role in the balance between lipid and carbohydrate metabolism. FABPs mediate fatty acid (FA) and/or hydrophobic ligand uptake, transport and targeting within their respective tissues. The mechanisms underlying these actions can give rise to both passive diffusional uptake and protein-mediated transmembrane transport of FAs. FABPs are expressed in adipocytes (A-FABP), brain (B-FABP), epidermis (E-FABP, also designated psoriasis-associated FABP or PA-FABP), muscle and heart (H-FABP, also designated mammary-derived growth inhibitor or MDGI), intestine (I-FABP), liver (L-FABP), myelin (M-FABP) and testis (T-FABP). MDGI is highly expressed in the myocardium, skeletal and smooth muscle fibers, lipid and/or steroid synthesizing cells and terminally differentiated epithelia of the respiratory, intestinal and urogenital tracts.
免疫組化的呈色深淺可反映抗原存在的數量,可作為定性、定位和定量的依據。
1.陽性細胞染色分布有三種類型:細胞漿、細胞核、細胞膜表面。大部分抗原見于細胞漿,可見于整個胞漿或部分胞漿
2.陽性細胞分布可分為灶型和彌漫性
3.由于細胞內含抗原量不同,所以染色強度不一。如果細胞之間染色強度相同,常提示其反應為非特異性
4.陽性細胞染色定位于單個細胞,且與陰性細胞相互交雜分布;而非特異性染色常不限于單個細胞,而是累及一片細胞。
5.切片邊緣、刀痕或褶皺區域,壞死或擠壓的細胞區,膠原結締組織等,常表現為相同的陽性染色強度,不能用于判斷陽性。
相關產品:
Integrin a7(integrin alpha 7) 整合素α7抗體
Integrin β1/CD29(integrin beta 1) 整合素β1抗體
Integrin α5/CD49e/VLA-5(Integrin αV) 整合素α5抗體
Integrin α6/CD49f/VLA-6(Integrin alpha6/Laminin Receptor) 整合素α6抗體
Integrin β3/CD61(Integrin beta 3) 整合素β3抗體
JAK1(Tyrosine-protein kinase JAK1; Janus kinase 1) 蛋白質*激酶JAK-1抗體
JAK2(Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2) 蛋白質*激酶JAK-2抗體
phospho JAK2(phospho-Tyr1007+Tyr1008) 磷酸化蛋白*激酶JAK-2抗體
JNK1/3 (c-Jun amino-terminal kinase 1/3) c-Jun氨基末端激酶1/3抗體
Jab1(c-Jun activation domain-binding protein1) Jun激活區域-連接蛋白1抗體
phospho-JNK1/2/3(pThr183/pTyr185) 抗磷酸化氨基末端激酶1/2/3抗體
JNK1/2/3 抗氨基末端激酶1/2/3抗體
p300/KAT3B 轉錄接頭蛋白EP300抗體
KCNA5(Potassium voltage-gated channel subfamily A member 5) 鉀電壓閥門通道混合器相關亞家族成員5抗體
Ki-67 Ki-67 Antigen抗體
Ki-67(Antigen identified by monoclonal antibody Ki 67) Ki67抗體
Ki-67(mo monoclonal) 小鼠Ki-67單克隆抗體
Kif14 protein 驅動蛋白家族Member14蛋白抗體
您感興趣的產品PRODUCTS YOU ARE INTERESTED IN
環保在線 設計制作,未經允許翻錄必究 .? ? ?
請輸入賬號
請輸入密碼
請輸驗證碼
請輸入你感興趣的產品
請簡單描述您的需求
請選擇省份